What is siParadigm?
Founded in 2004 and headquartered in Pine Brook, New Jersey, siParadigm operates as a specialized provider of advanced diagnostic informatics. The company distinguishes itself through a multi-modal approach to clinical testing, encompassing Disease-focused Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Cytogenetics/FISH, Flow Cytometry, and Morphology/IHC. Central to its value proposition is the Siportfolio, a proprietary reporting framework that correlates complex diagnostic data into actionable insights. By bridging the gap between raw laboratory data and clinical application, siParadigm serves as a critical partner for physicians and patients seeking high-fidelity diagnostic clarity in complex disease management.
The firm's infrastructure is designed to support the rigorous demands of modern oncology and pathology, providing the granular data necessary for personalized treatment pathways. As the healthcare industry shifts toward data-driven diagnostics, siParadigm's integration of informatics into traditional laboratory workflows positions it as a key player in the evolution of diagnostic medicine.
How much funding has siParadigm raised?
siParadigm has raised a total of $150K across 1 funding round:
Debt
$150K
Debt (2020): $150K with participation from PPP
Key Investors in siParadigm
PPP
Public-Private Partnership
What's next for siParadigm?
With the successful closure of this late-stage financing round, siParadigm is well-positioned to accelerate its strategic growth initiatives. The company is expected to focus on expanding its diagnostic portfolio and enhancing its informatics capabilities to meet the rising demand for integrated clinical reporting. Future efforts will likely prioritize the scaling of its laboratory operations and the deepening of its relationships with healthcare providers, ensuring that its diagnostic services remain scalable and accessible. As the company navigates this growth phase, the focus remains on maintaining high-quality diagnostic standards while exploring new frontiers in molecular pathology and patient-centric reporting, ultimately reinforcing its role as a cornerstone of the diagnostic informatics ecosystem.
See full siParadigm company page
